Cytotoxic progress at Avecia plants
Avecia's technologies for 'early phase' pharmaceutical development and manufacturing will be showcased at Informex. The company has built a major presence in chiral technology, through an ongoing series of acquisition and in-licensing moves.
'Technologies and, more importantly, combinations of technologies can offer substantially reduced costs of goods for our customers', said Avecia vp for pharmaceutical products Dr Peter Jackson.
In the last two years, Avecia has invested some US$60m (€57m) in early phase facilities. The latest is a new cytotoxics development suite at Grangemouth linked to development of anticancer drugs.
For scale-up and manufacture of advanced intermediates and actives for late phase trials and launched pharma products, Avecia has over 500m3 of specialised cGMP capacity at large scale UK facilities in Huddersfield, Billingham and Grangemouth.
Stand 1927